Table 2. Patients' characteristics after... | American Society of Hematology

Table 2.

Patients' characteristics after cyclosporin A (CyA) treatment

Patient no.	CyA therapy (mo)	Platelets (× 10⁹/L)		CyA stopped	Response duration (mo)		Outcome	Bleeding
Patient no.	CyA therapy (mo)	Before therapy	After therapy	CyA stopped	Total	Off CyA	Outcome	Before therapy	After therapy
1	14	15	325	Yes	20	6	CR	++	−
2	21	29	300	Yes	62	41	CR	++	−
3	86	18	225	No	86	—	MTR	+	−
4	37	20	260	No	37	—	MTR	++	−
5	3	10	118	Yes	37	34	PR	++	−
6	3	27	28	Yes	—	—	NR	+	+
7	18	28	255	Yes	28	18	CR	++	−
8	3	3	250	No	3	—	MTR	++	−
9	15	27	290	Yes	40	25	CR	++	−
10	12	12	280	Yes	60	48	CR	++	−
11	3	19	25	Yes	—	—	NR	+	+
12	30	25	215	No	30	—	MTR	+	−

Patient no.	CyA therapy (mo)	Platelets (× 10⁹/L)		CyA stopped	Response duration (mo)		Outcome	Bleeding
Patient no.	CyA therapy (mo)	Before therapy	After therapy	CyA stopped	Total	Off CyA	Outcome	Before therapy	After therapy
1	14	15	325	Yes	20	6	CR	++	−
2	21	29	300	Yes	62	41	CR	++	−
3	86	18	225	No	86	—	MTR	+	−
4	37	20	260	No	37	—	MTR	++	−
5	3	10	118	Yes	37	34	PR	++	−
6	3	27	28	Yes	—	—	NR	+	+
7	18	28	255	Yes	28	18	CR	++	−
8	3	3	250	No	3	—	MTR	++	−
9	15	27	290	Yes	40	25	CR	++	−
10	12	12	280	Yes	60	48	CR	++	−
11	3	19	25	Yes	—	—	NR	+	+
12	30	25	215	No	30	—	MTR	+	−

Patients 1 to 4 were described previously15; the information here represents a follow-up update. Patient 8 died of a myocardial infarction during CyA treatment.

CR indicates complete response; MTR, response to maintenance therapy; PR, partial response; NR, no response; ++, major bleeding; +, minor bleeding; and −, no bleeding.

View Large

This Feature Is Available To Subscribers Only